US OptionsDetailed Quotes
SKY250516C60000
- 0.00
- 0.000.00%
15min DelayClose Apr 30 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest60.00Strike Price0.00Turnover0.00%IV-30.64%PremiumMay 16, 2025Expiry Date26.50Intrinsic Value100Multiplier16DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.26Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Champion Homes Stock Discussion
Sign in to post a comment
The attention of AI Medteck stocks are rapidly increasing.
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...
116
14
285
The company's shift into profitability and increased capital utilization suggest successful reinvestment activities. This trend could lead to a multi-bagger performance. The stock's exceptional performance over the last five years indicates investor recognition.
Given the uncertainty from negative returns, it might be time to reduce portfolio risk. With the stock trading around its fair value, now may not be the best time to buy. The negative growth outlook increases the risk of holding the stock.
1
Multiple insider sales within a short timeframe, along with absence of insider purchases, makes analysts wary. High insider ownership doesn't rectify the dent in investor optimism due to recent share sales.
Skyline Champion's high earnings growth and decent ROE surpass industry averages thanks to efficient management and high earnings retention. Even though future earnings growth may slow, the firm's reinvestment strategy continues to fuel substantial earnings growth.
Despite the short term fall in the share price, Skyline's long term returns and growing profits suggest strong underlying business performance. The market seems cautious about the stock, possibly because the company only recently became profitable.
Data from Census Bureau: the average price for a traditional new home sold in Dec 2022 was $528,400 (including the land) whereas for new manufactured home the average price in Sep 2022 was $130,400 (without land).
$Champion Homes (SKY.US)$ $Cavco Industries (CVCO.US)$ $Berkshire Hathaway-B (BRK.B.US)$
$Champion Homes (SKY.US)$ $Cavco Industries (CVCO.US)$ $Berkshire Hathaway-B (BRK.B.US)$
1
80.00Upgrades
• $Allegiance (ABTX.US)$ : Raymond James Upgrades to Outperform from Market Perform - PT $43
• $Bunge (BG.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $106 (from $130)
• $Cerence (CRNC.US)$ : RBC Capital Upgrades to Sector Perform from Underperform - PT $27 (from $28)
• $First Mid Bancshares (FMBH.US)$ : Raymond James Upgrades to Outperform from Market Perform - PT $45
• $Lamar Advertising Co (LAMR.US)$ : Citigroup Up...
• $Allegiance (ABTX.US)$ : Raymond James Upgrades to Outperform from Market Perform - PT $43
• $Bunge (BG.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $106 (from $130)
• $Cerence (CRNC.US)$ : RBC Capital Upgrades to Sector Perform from Underperform - PT $27 (from $28)
• $First Mid Bancshares (FMBH.US)$ : Raymond James Upgrades to Outperform from Market Perform - PT $45
• $Lamar Advertising Co (LAMR.US)$ : Citigroup Up...
12
10
Gainers:
• $SpringWorks Therapeutics (SWTX.US)$ +19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase3DeFi Trial )
• $Roivant Sciences (ROIV.US)$ +7.1% (FDA has approved VTAMA (tapinarof) cream)
• $Ocugen (OCGN.US)$ +5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called Ne?Cart)
• $Champion Homes (SKY.US)$ +4.4% (In reaction to earnings）
• $NetEase (NTES.US)$ +4.1% (In...
• $SpringWorks Therapeutics (SWTX.US)$ +19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase3DeFi Trial )
• $Roivant Sciences (ROIV.US)$ +7.1% (FDA has approved VTAMA (tapinarof) cream)
• $Ocugen (OCGN.US)$ +5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called Ne?Cart)
• $Champion Homes (SKY.US)$ +4.4% (In reaction to earnings）
• $NetEase (NTES.US)$ +4.1% (In...
12
8
No comment yet
Buy n Die Together❤ :
73610841 : Adrian Nathaniel carter, I can’t tag him and we’re Facebook friends, does anyone know why?
Seth Beaty : Though you know if you bet against Cathie Wood, you’ll probably make money.
Rob banks : is there an ETF for this ai medical sector?
Chak : is it goid time yo
get into TEM ?
View more comments...